Hik­ma to take over sev­er­al as­sets from Xel­lia, in­clud­ing a US man­u­fac­tur­ing site

Gener­ic drug com­pa­ny Hik­ma is bol­ster­ing its port­fo­lio by ac­quir­ing parts of Xel­lia Phar­ma­ceu­ti­cals’ fin­ished dosage form busi­ness in the US.

This in­cludes Hik­ma tak­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.